Burkitt Lymphoma - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Burkitt Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Burkitt Lymphoma - Pipeline Review, H2 2014', provides an overview of the Burkitt Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Burkitt Lymphoma Overview 6
Therapeutics Development 7
Pipeline Products for Burkitt Lymphoma - Overview 7
Pipeline Products for Burkitt Lymphoma - Comparative Analysis 8
Burkitt Lymphoma - Therapeutics under Development by Companies 9
Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 10
Burkitt Lymphoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Burkitt Lymphoma - Products under Development by Companies 13
Burkitt Lymphoma - Products under Investigation by Universities/Institutes 14
Burkitt Lymphoma - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Seattle Genetics, Inc. 16
Celldex Therapeutics, Inc. 17
Constellation Pharmaceuticals, Inc. 18
Burkitt Lymphoma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
varlilumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SGN-CD19A - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NSC-678515 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AZD-6738 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SH-7139 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit BET for Cancer - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody Conjugated to Target CD20 for CLL and Burkitt Lymphoma - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
M-921 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SH-7133 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SH-7129 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Burkitt Lymphoma - Recent Pipeline Updates 41
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Burkitt Lymphoma, H2 2014 7
Number of Products under Development for Burkitt Lymphoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Burkitt Lymphoma - Pipeline by AstraZeneca PLC, H2 2014 15
Burkitt Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2014 16
Burkitt Lymphoma - Pipeline by Celldex Therapeutics, Inc., H2 2014 17
Burkitt Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Burkitt Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 41